Australia markets closed

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.10000.0000 (0.00%)
At close: 03:35PM AEDT
Full screen
Previous close0.1000
Bid0.0960 x 10000000
Ask0.1000 x 249000000
Day's range0.0960 - 0.1000
52-week range0.0930 - 0.1750
Avg. volume54,532
Market cap11.542M
Beta (5Y monthly)0.32
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Launching our most comprehensive test and expanding into new global markets

    MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24). GENE's pioneering initiatives in genomics-based tests place it at the forefront of precision medicine. Leading the world in risk predictio

  • GlobeNewswire

    Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

    MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17,

  • GlobeNewswire

    GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness

    MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels. These segments highlight geneType's potential to shape the future of proactive health management. Precision Medicine Takes Flight at Gold Coast Private